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Edited by Veli-Pekka LehtoAbstract Anti-VEGF treatment has become accepted ﬁrst-line
treatment for choroidal neovascularisation (CNV) in age-related
macular degeneration. However, VEGF-inhibition does not al-
ways lead to sustained CNV-reduction. In this study, the eﬀect
of rapamycin was superior to VEGF-inhibition in a co-culture
assay of endothelial cells (ECs) and retinal pigment epithelium
(RPE). Rapamycin reduced EC sprouting in groups that did
not respond to anti-VEGF treatment. Rapamycin did not induce
EC apoptosis, but reduced both VEGF-production in RPE and
the responsiveness of ECs to stimulation. Rapamycin might
therefore be a therapeutic option for CNV patients that do not
respond suﬃciently to the established anti-VEGF treatments.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Rapamycin1. Introduction
VEGF has been identiﬁed as one of the key molecules for the
formation of choroidal neovascularisation (CNV) in age-re-
lated macular degeneration (AMD) [1]. VEGF-inhibitors have
greatly improved vision prognosis for CNV patients over the
last 3 years. For the ﬁrst time, loss of visual acuity (VA) can
be prevented and even reverted in CNV patients [2]. Today,
two anti-VEGF substances (pegabtanib and ranibizumab)
are approved for intravitreal use in CNV patients [3–6]. Addi-
tionally, the humanized anti-VEGF antibody bevacizumab is
widely used for CNV treatment as an oﬀ-label therapy
[7–10]. All three substances share the property of preventing
VEGF from binding to its target receptor on endothelial cells.
However, the retinal expression of VEGF is not altered. It can
even be speculated that the inactivation of soluble VEGF mol-
ecules might induce a regulatory increase in VEGF produc-
tion. In consequence, the current anti-VEGF therapies have
to be re-administered on a monthly basis by intravitreal injec-
tion bearing all possible side eﬀects of repeated intraocular sur-
gery. Additionally, not all CNV patients respond suﬃciently to
anti-VEGF treatment and some patients show disease progres-
sion under treatment.*Corresponding author. Fax: +49 761 270 4174.
E-mail address: hansjuergen.agostini@uniklinik-freiburg.de (H.T.
Agostini).
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doi:10.1016/j.febslet.2008.08.005Expression of VEGF can be induced by multiple cellular
pathways: Hypoxia leads to the expression of HIF1a that
in turn induces VEGF expression; a diﬀerent pathway of
VEGF induction is mediated by pro-inﬂammatory cytokines
such as TNF-a and TGF-b2 [11]. VEGF can therefore be
viewed as a ﬁnal common angiogenic pathway transducing
pro-angiogenic signals from a variety of sources towards
the uniform response of blood vessel sprouting. Instead of
targeting the VEGF molecule at the end of the angiogenic
cascade, it might be a more causative approach to alter the
angiogenic baseline situation leading to VEGF expression
and vessel sprouting.
One possible candidate to disrupt the angiogenic signalling
cascade upstream of VEGF-expression is rapamycin. Rapa-
mycin has been shown to possess both anti-tumor as well
as anti-angiogenic properties [12,13]. Rapamycin can decrease
VEGF production in stromal cells [14]. Additionally, rapamy-
cin alters the response of endothelial cells to VEGF stimula-
tion [12]. With regard to ophthalmology, the anti-angiogenic
eﬀects of rapamycin have been evaluated both in rodent mod-
els of corneal neovascularisation [15,16] as well as retinal and
choroidal angiogenesis [17]. In both models, rapamycin eﬀec-
tively reduced neovascularisation. Recently, the ﬁrst interim
results of two clinical phase I trials for intravitreally admin-
istered rapamycin in patients with exsudative AMD or
diabetic macular edema have been reported [18,19]. The
authors report no safety issues after a single intravitreal injec-
tion of rapamycin. Various other groups have conﬁrmed the
apparent safety of intravitreally administered rapamycin in
diﬀerent animal species [20–22]. However, there is no in vitro
data available that quantiﬁes the anti-angiogenic eﬀect of
rapamycin, compares it to the established anti-VEGF thera-
pies and investigates the possible side eﬀects on a cellular
level.
As the retinal pigment epithelium (RPE) is the main pro-
ducer of CNV-related VEGF [1], this study aims to quantify
the eﬀect of rapamycin on RPE-induced angiogenesis and to
clarify parts of the mechanisms by which rapamycin might
inhibit CNV-related angiogenesis with a special focus on ther-
apy-induced apoptosis.2. Materials and methods
2.1. Monolayer and spheroidal cell culture
Human umbilical vein endothelial cells (HUVECs) were obtained
from Promocell (Heidelberg, Germany) and used from passages 2
to 7 for sprouting experiments. Cells were cultured as monolayersblished by Elsevier B.V. All rights reserved.
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(EGM, Promocell). The preparation of EC spheroids was performed
as described [23]. Brieﬂy, cells were harvested from subconﬂuent
monolayers by trypsination and suspended in EGM containing
10% FBS and 0.25% (w/v) carboxymethylcellulose (Sigma, Munich,
Germany). Five hundred cells were seeded together in one hanging
drop to assemble into a single spheroid within 24 h at 37 C, 5%
CO2. Thirty spheroids were used per well in the spheroidal sprouting
model (see below). RPE cells were cultivated from surgically re-
moved CNV-membranes (CNV-RPE) [24]. Control human RPE
(hRPE) was obtained from human donor eyes without AMD
changes after informed consent of the patient and in accordance
with the provisions of the Declaration of Helsinki and the Ethics
committee at the University of Freiburg. ARPE-19 cells (ATCC
No. CLR-2302) were kept at the same conditions as the isolated
RPE [24].2.2. Spheroidal sprouting model
Sprouting of EC spheroids in a matrix of type I collagen has been
described before [25,26]. One day prior to preparation of spheroid
gels, 40000 RPE cells/well were seeded into 24-well plates to estab-
lish a preformed RPE monolayer for stimulation of EC spheroids.
After 24 h, 0.5 ml collagen gels containing 30 EC spheroids were
added on top of the RPE monolayers. Freshly prepared gels were
transferred rapidly into a humidiﬁed incubator (37 C, 5% CO2)
and after polymerization, 0.1 ml EBM (Promocell) was added per
well containing angiogenic inhibitors as indicated. Bevacizumab
was from Roche (Grenzach-Wyhlen, Germany), ranibizumab was
from Novartis (Nu¨rnberg, Germany), rapamycin was from Sigma
(Munich, Germany) and LY294002 was from Calbiochem (Merck,
Darmstadt, Germany). The concentrations of bevacizumab (312 lg/
ml) and ranibizumab (125 lg/ml) were deducted from the concentra-
tions used clinically and were well in the saturation range in dose–re-
sponse experiments. After 24 h at 37 C, 5% CO2, gels were
photographed and spheroid sprouting was measured. The sprout
lengths of 10 randomly selected spheroids were measured and mean
sprout length was calculated for each group. Control sprout lengths
(CTR) were measured in groups without inhibitor. Groups contain-
ing inhibitors were analyzed relative to CTR. Results are expressed
as means + S.E.M.2.3. Quantiﬁcation of apoptosis in endothelial cell spheroids
For quantiﬁcation of in-gel apoptosis, spheroid gels containing 30
EC spheroids were harvested at diﬀerent time points and stored at
80 C. After thawing, gels were centrifuged at 1500 · g and
histone-associated DNA fragments were quantiﬁed using a cell
death detection ELISA (Roche) following the manufacturers
instructions.2.4. Life/death staining and confocal microscopy
Life/death staining of EC spheroids was performed by incubating
the spheroid gels with calcein 0.075 ll/well and ethidiumbromide
0.75 ll/well (red) from Molecular Probes (Paisley, UK). After 30 min
at 37 C, 5% CO2 the gels were transferred onto cover slips and confo-
cal microscopy was performed using a Leica DM IRBE confocal laser
scanning microscope.3. VEGF ELISA
For measurements of VEGF concentrations in cell culture
supernatants, conditioned media (CM) was generated from
RPE cells in conﬂuent monolayer cell cultures with endothelial
basal medium (EBM, Promocell) +/ rapamycin. After 24 h,
the medium was recovered, pre-cleared by centrifugation and
used for the ELISA assay following the manufacturers proto-
col (R&D, Wiesbaden, Germany). Total protein of RPE mon-
olayers was measured using the micro BCA test (Pierce,
Rockford, USA).4. Results
4.1. Anti-angiogenic eﬀect of rapamycin on RPE-induced EC
sprouting
RPE-induced sprouting angiogenesis was assessed using a
3D co-culture model of RPE monolayer and EC spheroids.
In this model system, EC spheroids form tube-like sprouts in
response to angiogenic stimulation from the RPE monolayer.
Anti-VEGF treatment with bevacizumab or ranibizumab re-
duced RPE-induced sprouting in groups with normal human
RPE (hRPE). However, VEGF-inhibition had only limited ef-
fect in groups where angiogenic stimulation was provided by
RPE from human CNV membranes (CNV-RPE) (Fig. 1). In
contrast to the VEGF-inhibitors, rapamycin inhibited RPE-in-
duced sprouting both in hRPE as well as in CNV-RPE groups
in a dose-dependent manner. The unspeciﬁc PI3K/Akt inhibi-
tor Ly294002 almost completely abolished RPE-induced EC
sprouting in all groups.4.2. Quantiﬁcation of apoptosis in EC spheroids treated with
rapamycin
In order to evaluate if EC apoptosis might be the cause for
sprout reduction in rapamycin-treated groups, apoptosis-asso-
ciated DNA degradation was measured in EC spheroids (Fig.
2A). Additionally, EC spheroids were stained for cell viability
(Fig. 2B). The presence of rapamycin did not induce apoptosis
of EC spheroids. EC spheroids treated with Ly294002, how-
ever, showed increased DNA degradation and an increase in
cell death staining.
4.3. VEGF-expression in RPE cells treated with rapamycin
Rapamycin reduces VEGF expression in both tumor and
normal cells [12,14,27,28]. Therefore, we measured VEGF lev-
els in RPE-cells treated with rapamycin. Rapamycin reduced
VEGF protein expression in CNV-RPE cells from 177 to
122 pg VEGF/mg total protein (Fig. 3A). However, rapamy-
cin-induced sprout reduction could not be rescued by addition
of exogenous VEGF (Fig. 3B).5. Discussion
This study investigates the anti-angiogenic eﬀect of rapamy-
cin in an in vitro model of RPE-induced sprouting angiogene-
sis and compares it to the clinically established VEGF-
inhibitors. In this model, VEGF-inhibitors were not able to
completely abolish EC sprouting induced by CNV-RPE (Fig.
1). The concentrations of bevacizumab (312 lg/ml) and rani-
bizumab (125 lg/ml) in this assay were deducted from the con-
centrations used in clinical practice and were well in the
saturation range in dose–response experiments. It is known,
that CNV-membranes can express a variety of diﬀerent growth
factors such as FGF-2, PDGF, IGF-1 and TGF-beta that can
partially compensate for loss of VEGF-stimulation [29–33].
The CNV-RPE used in our study has been characterized
earlier [24,32,34] and has been found to express signiﬁcant lev-
els of FGF2 in addition to VEGF [35]. The fact that FGF2
elicits its angiogenic eﬀect via VEGF-dependent as well as
VEGF-independent pathways [36–39] might explain why
CNV-RPE can still exert angiogenic stimulation under
VEGF-inhibition.
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Fig. 1. Normal human RPE (hRPE) as well as CNV-derived RPE (CNV-RPE) induce sprouting of EC spheroids. Anti-VEGF substances
(ranibizumab, bevacizumab) reduce EC sprouting only in groups stimulated by hRPE. Rapamycin (Rapa), in contrast, reduces EC sprouting both in
hRPE as well as in CNV-RPE groups in a dose-dependent manner. Ly294002 (LY) completely blocks sprouting in all groups. CTR, control
sprouting without inhibitor (set to 100%) * signiﬁes P < 0.05 vs. CTR (Tukey–Kramer HSD, accounting for multiple testing).
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Fig. 2A. Apoptosis of EC spheroids in collagen gels stimulated by CNV-RPE monolayer. Addition of rapamycin (500 ng/ml) induced only little
apoptosis of EC spheroids over 22 h of incubation. In contrast, addition of Ly294002 (15 lM) markedly induced EC apoptosis within the ﬁrst 6 h.
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Fig. 2B. Confocal pictures of life/death staining in EC spheroids. Life cells stain green, dead cells stain red. In RPE-stimulated EC spheroids without
inhibitor (CTR), only few dead cells were found. Spheroids treated with rapamycin (500 ng/ml) show reduced sprouting but only few dead cells.
Spheroids treated with Ly294002 (15 lM), in contrast, display reduced sprouting associated with an increase in dead cells.
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sprouting in all RPE groups in a dose-dependent manner.
Importantly, rapamycins anti-angiogenic eﬀect was not associ-
ated with induction of EC apoptosis, whereas LY294002 did
induce EC apoptosis (Fig. 2). This diﬀerence between rapamy-0
40
80
120
160
200
CNV-RPE CTR CNV-RPE Rapa
pg
 V
EG
F 
/ m
g 
to
ta
l c
el
l p
ro
te
in
p = 0.03
Fig. 3A. VEGF-production of CNV-RPE within 24 h. Addition of
rapamycin (500 ng/ml) decreases VEGF production by 31%. CTR,
control group without rapamycin P-value was calculated using
unpaired t-test; error bars signify S.T.D.
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Fig. 3B. EC spheroid sprouting stimulated by CNV-RPE. Addition of VEGF
group (CTR). Addition of rapamycin inhibits EC sprouting. This inhibition c
by CNV-RPE without additional VEGF. Error bars signify S.E.M.; P-valuecin and LY294002 might be due to the fact that rapamycin
blocks only one output of the PI3K/Akt signalling pathway
(mTOR), while LY294002 interrupts all Akt-mediated survival
pathways [40,41].
Regarding the mechanisms by which rapamycin exerts its
anti-angiogenic eﬀect, we found a dual mode of action. On
the one hand, rapamycin reduced VEGF expression in RPE
cells (Fig. 3A). On the other hand, addition of exogenous
VEGF was not able to rescue sprouting after rapamycin treat-
ment (Fig. 3B). This was true although the dose of exogenously
added VEGF was exceedingly higher than the VEGF-reduc-
tion through rapamycin. This ﬁnding suggests an inhibitory ef-
fect of rapamycin that is resistant to VEGF-stimulation. One
possible mechanism for VEGF-resistant sprout inhibition
through rapamycin could be an inhibition of cell cycle progres-
sion and protein translation [12,42].
By inducing such a cytostatic response in activated ECs, rap-
amycin might help to reduce CNV-activity in those patients
who do not respond suﬃciently to the established anti-VEGF
treatment regimes. Additionally, rapamycin could lower
VEGF expression in RPE cells and could thus help to reduce
the number of anti-VEGF injections needed to control CNV
activity. Compared to the eﬀect of LY294002, rapamycin
was well tolerated by both RPE and endothelial cells in vitro.Rapa 500ng/ml Rapa 500ng/ml + 
VEGF 25ng/ml
p = 0.11
does not further increase EC sprouting above RPE-stimulated control
annot be rescued by addition of VEGF. CTR, control group stimulated
s were calculated using t-tests corrected for multiple testing.
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clarify the role of rapamycin in CNV treatment and rule out
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